Home » Avenue Therapeutics and AnnJi Ink Deal Over Kennedy’s Disease Candidate
Avenue Therapeutics and AnnJi Ink Deal Over Kennedy’s Disease Candidate
Drugs Commercial Operations
Avenue Therapeutics has licensed AnnJi Pharmaceutical’s AJ201, an investigational treatment for spinal and bulbar muscular atrophy, also known as Kennedy’s disease, a rare genetic motor neuron disorder primarily affecting men.
AJ201 is designed to modify the disease through several mechanisms, including degradation of an abnormal androgen receptor protein.
Taiwan-based AnnJi completed a phase 1 trial of the candidate in 2021 which demonstrated the molecule’s safety. AJ201 is currently being studied in a phase 1b/2a trial.
Under the licensing deal, AnnJi will receive an upfront payment of $3 million and is eligible for unspecified future milestone payments.